GCM
PPH icon

Glaxis Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Glaxis Capital Management’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,000
Closed -$272K – 75
2024
Q1 		$272K Buy
+3,000
New +$263K 0.5% 56

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCIA
Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return
FPGK
Financial Partners Group (Kansas) Overland Park, Kansas $836M AUM 21.04% 1-Year Est. Return

Glaxis Capital Management's PPH Position: Q2 2024 in Review

Glaxis Capital Management sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2024, closing a stake of 3,000 shares — an estimated $272K sold.

Glaxis Capital Management first reported a position in PPH in Q1 2024 and held it in 1 quarter. The position peaked at $272K in Q1 2024. 140 funds tracked by Wall St. Rank hold PPH as of Q2 2024.

  • Glaxis Capital Management reported no remaining VanEck Pharmaceutical ETF position as of Q2 2024 after selling out during the quarter.
  • Glaxis Capital Management sold 3,000 VanEck Pharmaceutical ETF shares in Q2 2024, an estimated $272K.
  • Glaxis Capital Management first reported a position in VanEck Pharmaceutical ETF in Q1 2024 and held it in 1 quarter.
  • Glaxis Capital Management's VanEck Pharmaceutical ETF position peaked at $272K in Q1 2024.
  • 140 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2024.

Based on Glaxis Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.